srch

Boston Pharmaceuticals Inc., a startup backed with a $600 million funding commitment from a single investor, is bulking up its portfolio of ...

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for …

WHAT WE DO. We acquire innovative molecules from pharmaceutical and biotechnology companies and transform them into differentiated therapeutics that improve patients’ lives. We bring drug development programs into our pipeline as early as candidate selection and advance candidates to an appropriate value inflection point.

Boston Pharmaceuticals leverages a highly experienced drug development team to generate clinical data to create value for their organization and their ...

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

Sep 04, 2020 · Boston-based Aerovate Therapeutics, a biotech startup focused on rare cardiopulmonary disease, raised $72.6M in Series A funding led by Sofinnova Investments, with participation from Atlas Venture ...

Information on valuation, funding, acquisitions, investors, and executives for Boston Pharmaceuticals. Use the PitchBook Platform to explore the full profile.

Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced drug development team to advance a portfolio of high value ca... Read More. Headquarters: 55 Cambridge Pkwy, Ste 402, Cambridge, Massachusetts, 02142, United States.

Information on valuation, funding, acquisitions, investors, and executives for Boston Pharmaceuticals. Use the PitchBook Platform to explore the full ...

Information on valuation, funding, acquisitions, investors, and executives for Boston Pharmaceuticals. Use the PitchBook Platform to explore the full profile.

Boston Pharmaceuticals is agnostic to therapeutic area specialization, ... but constrained financial resources for R&D, Boston Pharmaceuticals offers an ...

Under the terms of the agreement, Boston Pharmaceuticals acquired worldwide rights ... Financial terms of the agreement were not disclosed.

14.10.2021 · Watertown biotech Neumora Therapeutics, a clinical-stage company pioneering precision medicines for brain diseases, has announced its launch. Neumora was founded as a response to the lack of targeted, effective medicines for brain diseases and the high neuroscience drug development failure rate and has raised over $500 million, including a $100 million equity …

17.08.2020 · Founded: 2008 Focus: Pharmaceutical Software What they do: InviCRO supports the efforts of pharmaceutical researchers by offering a comprehensive suite of software applications and technologies for use in targeting and conducting drug testing trials. Their team of over 200 researchers utilizes analytical science to discover actionable datasets and deliver them to their …

24.12.2021 · Company announcement – No. 77 / 2021. Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 Copenhagen, DK and Boston, MA, December 24, 2021 – Zealand Pharma A/S ...

Complementing the Boston Pharmaceuticals team is a network of best-in-class development partners strategically integrated into our programs. This blended model allows us to flexibly scale across programs, return more value to our partners and ultimately bring the best medicines to patients.

Former Sanofi CEO Chris Viehbacher was handed the keys to a big biotech fund from Gurnet Point Capital a few months ago, ...

Boston Pharmaceuticals leverages a highly experienced drug development team to generate clinical data to create value for their organization and their partners. They have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for their diverse pipeline.

04.09.2020 · The VC summer slowdown may be real after all. Last month, Boston-area startups and tech firms raised a collective $1.3B—a formidable number, but …

Our team of proven drug development experts. Single-minded focus on rapidly achieving clinically meaningful endpoints. Full and separate funding for each ...

Boston Pharmaceuticals leverages a highly experienced drug development team to generate clinical data to create value for their organization and their partners. They have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for their diverse pipeline.

Under the terms of the agreement, Boston Pharmaceuticals acquired worldwide rights ... Financial terms of the agreement were not disclosed.

Full and separate funding for each program. Flexible, fast and creative approach to transactions ... Boston Pharmaceuticals, Inc. 55 Cambridge Parkway, Suite 402 ...

Boston Pharmaceuticals returned ARN-6039 or BOS-172767 to Arrien Pharmaceuticals in January 2021 and the company successfully relicensed to Xenter, Inc., in June 2021. Our initial licensing of ARN-6039 to Boston Pharmaceuticals, subsequently to Xenter, Inc., was encouraging, and further validates ARN-6039 importance in targeting ROR-γt/IL-17 axis.

Boston Pharmaceuticals top competitors are Sumitomo Dainippon Pharma Oncology and they have annual revenue of $17.3M and 86 employees. ... Total Funding:N/A.

CAREERS. Welcome to Boston Pharmaceuticals. Founded in 2015, Boston Pharmaceuticals is an early phase drug development company dedicated to rapidly transforming the right molecules into the best medicines™ for patients. Who we are. We are a team of veteran drug developers who are passionate about transforming the right molecules into the best ...